Skip to main content
Erschienen in: Hepatology International 3/2011

01.09.2011 | Original Article

Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature

verfasst von: A. K. Singal, C. M. Stanca, V. Clark, L. Dixon, C. Levy, J. A. Odin, M. I. Fiel, S. L. Friedman, N. Bach

Erschienen in: Hepatology International | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

Information about the natural history of small duct primary sclerosing cholangitis (SDPSC) remains scant despite literature suggesting that it constitutes 6–16% of all cases of primary sclerosing cholangitis (PSC). We combined clinical data on SDPSC cases from two tertiary care institutions with liver transplantation programs with the aim of studying the natural history of SDPSC.

Methods

Medical records of 25 individuals with SDPSC were reviewed. Diagnosis of SDPSC was based on liver biopsy findings consistent with PSC, a normal cholangiogram, and elimination of known causes of secondary sclerosing cholangitis. Demographic information, symptoms, past medical history, laboratory values, and histologic data were evaluated. Our primary outcome measure was liver transplantation or death. Secondary outcome measures included evidence of end-stage liver disease, development of cholangiocarcinoma, and/or the development of classic PSC on a repeat cholangiogram.

Results

Data on 25 individuals (13 males, 12 females; mean age 40 ± 15 years) diagnosed with SDPSC were analyzed. Upon presentation, 11 patients had symptoms including abdominal pain, fatigue, and pruritus. Inflammatory bowel disease was present in 14 patients (56%) at diagnosis. On initial liver biopsy, 60% had early-stage disease (I or II) and none had cirrhosis. On follow-up (1–168 months, median 17 months), malignancy or progression to classic large duct PSC was not noted. Two (8%) patients had evidence of varices and one of the two also developed ascites; one of these patients underwent liver transplantation and the other one died due to sepsis.

Conclusions

SDPSC, a mild disease at presentation typically runs a benign course and likely is not an early stage of classic PSC. Further studies with a control group of classic PSC and longer follow-up are needed to study the natural history of SDPSC.
Literatur
1.
Zurück zum Zitat Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus EV Jr, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125:1364–1369PubMedCrossRef Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus EV Jr, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125:1364–1369PubMedCrossRef
2.
Zurück zum Zitat Kim WR, Ludwig J, Lindor KD. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol. 2000;95:1130–1138PubMedCrossRef Kim WR, Ludwig J, Lindor KD. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol. 2000;95:1130–1138PubMedCrossRef
3.
Zurück zum Zitat Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med. 1985;102:581–587PubMed Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med. 1985;102:581–587PubMed
4.
7.
Zurück zum Zitat Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology. 2002;35:1494–1500PubMedCrossRef Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology. 2002;35:1494–1500PubMedCrossRef
8.
Zurück zum Zitat Bjornsson E, Boberg KM, Cullen S, Fleming K, Clausen OP, Fausa O, Schrumpf E, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut. 2002;51:731–735PubMedCrossRef Bjornsson E, Boberg KM, Cullen S, Fleming K, Clausen OP, Fausa O, Schrumpf E, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut. 2002;51:731–735PubMedCrossRef
9.
Zurück zum Zitat Broome U, Glaumann H, Lindstom E, Loof L, Almer S, Prytz H, Sandberg-Gertzen H, et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol. 2002;36:586–589PubMedCrossRef Broome U, Glaumann H, Lindstom E, Loof L, Almer S, Prytz H, Sandberg-Gertzen H, et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol. 2002;36:586–589PubMedCrossRef
10.
Zurück zum Zitat Nikolaidis NL, Giouleme OI, Tziomalos KA, Patsiaoura K, Kazantzidou E, Voutsas AD, Vassiliadis T, et al. Small-duct primary sclerosing cholangitis. A single-center seven-year experience. Dig Dis Sci. 2005;50:324–326PubMedCrossRef Nikolaidis NL, Giouleme OI, Tziomalos KA, Patsiaoura K, Kazantzidou E, Voutsas AD, Vassiliadis T, et al. Small-duct primary sclerosing cholangitis. A single-center seven-year experience. Dig Dis Sci. 2005;50:324–326PubMedCrossRef
11.
Zurück zum Zitat Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis. 2006;26:22–30PubMedCrossRef Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis. 2006;26:22–30PubMedCrossRef
12.
Zurück zum Zitat Schaffner F. Cholestasis. London: W B Saunders; 1992. p. 371–376 Schaffner F. Cholestasis. London: W B Saunders; 1992. p. 371–376
13.
14.
Zurück zum Zitat Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 1978;379:103–112PubMedCrossRef Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 1978;379:103–112PubMedCrossRef
15.
Zurück zum Zitat Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102:1042–1049PubMedCrossRef Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102:1042–1049PubMedCrossRef
16.
Zurück zum Zitat LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, Hoofnagle JH. Primary sclerosing cholangitis: summary of a workshop. Hepatology. 2006;44:746–764PubMedCrossRef LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, Hoofnagle JH. Primary sclerosing cholangitis: summary of a workshop. Hepatology. 2006;44:746–764PubMedCrossRef
17.
Zurück zum Zitat Bjornsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, Boberg KM, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134:975–980PubMedCrossRef Bjornsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, Boberg KM, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134:975–980PubMedCrossRef
18.
Zurück zum Zitat Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–678 Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–678
19.
Zurück zum Zitat Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, Hultcrantz R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36:321–327PubMedCrossRef Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, Hultcrantz R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36:321–327PubMedCrossRef
20.
Zurück zum Zitat Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523–526PubMedCrossRef Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523–526PubMedCrossRef
Metadaten
Titel
Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature
verfasst von
A. K. Singal
C. M. Stanca
V. Clark
L. Dixon
C. Levy
J. A. Odin
M. I. Fiel
S. L. Friedman
N. Bach
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Hepatology International / Ausgabe 3/2011
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-011-9260-4

Weitere Artikel der Ausgabe 3/2011

Hepatology International 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.